Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M2jMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzETWM2OD1yLkCwOlY6KM7:TR?= MmLMV2FPT0WU
MV-4-11 NV3HV3pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13J[2lEPTB;MD6wNVU5PiEQvF2= NXnYfmpkW0GQR1XS
NKM-1 NYTMT4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPtSY1KSzVyPUCuNFE3QTlizszN Mlz5V2FPT0WU
ML-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\v[2lEPTB;MD6wNVk5OyEQvF2= NYq0VXk5W0GQR1XS
BV-173 NXKyfIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjobZE1UUN3ME2wMlAzOzF2IN88US=> Mm\ZV2FPT0WU
RS4-11 M1TOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInkSlhKSzVyPUCuNFI2QDdizszN Mn:3V2FPT0WU
HL-60 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHCTWM2OD1yLkCyPVA5KM7:TR?= MY\TRW5ITVJ?
KY821 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;GZoVGUUN3ME2wMlAzQTd3IN88US=> M3LHOnNCVkeHUh?=
ECC10 NVnhTHJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTkbpZKSzVyPUCuNFM4QTJizszN MkPuV2FPT0WU
NCI-H720 NGXk[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrHTWM2OD1yLkC0NFEyKM7:TR?= MYXTRW5ITVJ?
QIMR-WIL NWfnTWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMESyPFch|ryP NW\GfGdqW0GQR1XS
KG-1 NW[4SlVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMES0PFYh|ryP NYT1VYV7W0GQR1XS
TGW NEXiOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlWmVxUUN3ME2wMlA1PjN|IN88US=> M4nDUXNCVkeHUh?=
ATN-1 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LxOmlEPTB;MD6wOFc{OyEQvF2= NX23fXdTW0GQR1XS
RH-18 M{j5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDEOIxKSzVyPUCuNFYxPDhizszN MmrrV2FPT0WU
EW-18 M2PB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jjUmlEPTB;MD6wOlg1OSEQvF2= MYTTRW5ITVJ?
NB17 NFzS[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLkZYJHUUN3ME2wMlA4OTJ2IN88US=> M1rjSHNCVkeHUh?=
SK-NEP-1 NYPoNYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLxTWM2OD1yLkC3NlE{KM7:TR?= M4jlTHNCVkeHUh?=
P12-ICHIKAWA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnqeHNVUUN3ME2wMlA4Pzd6IN88US=> NGrmdIJUSU6JRWK=
KARPAS-45 M{XBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnHfHJKSzVyPUCuNFc5OTVizszN M2jxdHNCVkeHUh?=
EW-3 M2XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEiwOVMh|ryP M2nvNXNCVkeHUh?=
NB13 M4i5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEiyNFMh|ryP M4jPUXNCVkeHUh?=
NCI-H209 M3y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7GTGlKSzVyPUCuNFg4ODRizszN NVTiNFlxW0GQR1XS
NCI-H1092 NWnJSmlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMUCyO|Uh|ryP M3Lsb3NCVkeHUh?=
NH-12 NWX6RVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[0cmlEPTB;MD6xNFc1PCEQvF2= MXzTRW5ITVJ?
697 M3zPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XUSGlEPTB;MD6xNFg{QSEQvF2= NGj2UnNUSU6JRWK=
KE-37 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXFTWM2OD1yLkGxN|ch|ryP MVLTRW5ITVJ?
MOLT-4 M173XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUWxOlkh|ryP NHrJRlBUSU6JRWK=
CHP-134 NHrUTWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMU[zNFYh|ryP M1fJTXNCVkeHUh?=
D-283MED NV[3XZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjjd4FkUUN3ME2wMlE4Pjh4IN88US=> Mni1V2FPT0WU
LU-135 NUHId3J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPBc2FKSzVyPUCuNVg2PTJizszN MVLTRW5ITVJ?
LU-134-A MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzyTlhKSzVyPUCuNVg3PzFizszN NVj3T2JGW0GQR1XS
EM-2 NIK5OZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyTFRKSzVyPUCuNVk6OThizszN MXPTRW5ITVJ?
LU-139 NWL5PVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmyelFuUUN3ME2wMlIxPDl6IN88US=> MlnKV2FPT0WU
ALL-PO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfPRldKSzVyPUCuNlE6QDhizszN NFzlUmxUSU6JRWK=
NB12 NVv6TnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HmbmlEPTB;MD6yN|EyPSEQvF2= NULTdHhuW0GQR1XS
KP-N-YN NU\ofWY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHMNndKSzVyPUCuNlM2PzNizszN MYHTRW5ITVJ?
BEN NFW2R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T6dmlEPTB;MD6yN|k3QCEQvF2= MVPTRW5ITVJ?
HCC1569 NEK2dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nIWWlEPTB;MD6yOVExPiEQvF2= MlK2V2FPT0WU
HuO9 NULM[3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HBd2lEPTB;MD6yOlcyPSEQvF2= NWDPeZJ6W0GQR1XS
WM-115 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrrSJlKSzVyPUCuNlc4OzhizszN MVvTRW5ITVJ?
CCRF-CEM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwM{O1Nlkh|ryP MYfTRW5ITVJ?
IST-SL1 NGfWUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\0V3BuUUN3ME2wMlM2OzR|IN88US=> NETpOXZUSU6JRWK=
BE-13 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrac3AxUUN3ME2wMlM3PDV7IN88US=> MmDXV2FPT0WU
COR-L88 NFjSXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;PTWM2OD1yLkO2OVQh|ryP NGHOd2lUSU6JRWK=
DOHH-2 M1zvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX6NJlIUUN3ME2wMlQyODJ|IN88US=> NUjRbIY2W0GQR1XS
A704 NXTybHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlryTWM2OD1yLkSyOlch|ryP NHP0XmJUSU6JRWK=
KNS-81-FD M1vzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNESwNVch|ryP MX7TRW5ITVJ?
RPMI-8226 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\sfZpYUUN3ME2wMlQ2PjV{IN88US=> MXTTRW5ITVJ?
TGBC24TKB MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nhSWlEPTB;MD60OVc4QCEQvF2= Mn\yV2FPT0WU
NCI-H1304 NWPkXlQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfOTVNKSzVyPUCuOFYyPTdizszN MYrTRW5ITVJ?
MOLT-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjmSnBlUUN3ME2wMlQ3PjF|IN88US=> MX;TRW5ITVJ?
EW-22 M3Pqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nKdmlEPTB;MD60OlY4OSEQvF2= NV\EcFNYW0GQR1XS
MS-1 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjab|dKSzVyPUCuOFY6OzNizszN M4Tw[3NCVkeHUh?=
RMG-I NFK2VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\2XGlEPTB;MD60PVQ3PCEQvF2= NX23c|hWW0GQR1XS
NTERA-S-cl-D1 M16wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPPS3BKSzVyPUCuOVAxOTlizszN MkfFV2FPT0WU
NCI-H1048 NH;HOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHJO5VqUUN3ME2wMlUxQTV|IN88US=> MWrTRW5ITVJ?
SW1417 M3rtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\DTJh2UUN3ME2wMlU2PDN6IN88US=> MoDHV2FPT0WU
DB M2e3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTFTWM2OD1yLkW3NFgh|ryP Mn3GV2FPT0WU
MEG-01 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNUizNkDPxE1? NXrEb|B4W0GQR1XS
EW-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3U4t3UUN3ME2wMlU5OzRzIN88US=> NW[wT4ZFW0GQR1XS
LAMA-84 NHvsXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfVbpNFUUN3ME2wMlU6OjB5IN88US=> NGfRbZRUSU6JRWK=
J-RT3-T3-5 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPmZ2NKSzVyPUCuOlA5ODhizszN MY\TRW5ITVJ?
MOLT-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjyfY9KSzVyPUCuOlUzPjRizszN MmfCV2FPT0WU
DU-4475 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDzUFJyUUN3ME2wMlY2PDJ5IN88US=> M2TaSnNCVkeHUh?=
HAL-01 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXkfYRKSzVyPUCuO|I2PDlizszN MUfTRW5ITVJ?
RD MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTCTWM2OD1yLke1PFk6KM7:TR?= MmD4V2FPT0WU
OAW-28 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHUU5ZKSzVyPUCuO|g{PyEQvF2= MWLTRW5ITVJ?
HCC38 MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXFZ2FKSzVyPUCuPFAyQSEQvF2= M3G4N3NCVkeHUh?=
NMC-G1 NGTkSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv3TWM2OD1yLkixNVIyKM7:TR?= NH6x[HdUSU6JRWK=
EW-16 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jnW2lEPTB;MD64NVMzQCEQvF2= NGP2R4VUSU6JRWK=
DU-145 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwOEm5NlMh|ryP NFnrV|lUSU6JRWK=
HPAF-II MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwOUK2Nlgh|ryP NXHueGROW0GQR1XS
A427 NUnxOFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDBRVJKSzVyPUCuPVMxOjJizszN NU\QcHg{W0GQR1XS
PA-1 NGPUTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwOUW2OFIh|ryP NETifJJUSU6JRWK=
OAW-42 NH21fJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfzXXdKSzVyPUCuPVYyPDZizszN M3jYWHNCVkeHUh?=
L-428 M3\XXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juUmlEPTB;MT6wNVI2KM7:TR?= MUTTRW5ITVJ?
COLO-824 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\hXoxKSzVyPUGuNFE4ODhizszN NFzVTnNUSU6JRWK=
P30-OHK M4Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHaTWM2OD1zLkC0Olg5KM7:TR?= NUHNWphJW0GQR1XS
NCI-H2170 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfyfHdKSzVyPUGuNFYzOyEQvF2= M1nhd3NCVkeHUh?=
HCC2998 M3K4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMEexN|Uh|ryP MmW5V2FPT0WU
NB14 NUL4eGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;vTWM2OD1zLkGzO|Q5KM7:TR?= NEjsdFhUSU6JRWK=
TGBC1TKB MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe0Z|BKSzVyPUGuNVQyPTJizszN NGK2RlVUSU6JRWK=
KP-N-YS NVL6U2pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zZZ2lEPTB;MT6xOlI{PiEQvF2= NWfURXpGW0GQR1XS
CAL-120 M3jtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\nTWM2OD1zLkG2OFI6KM7:TR?= M1S3WXNCVkeHUh?=
SBC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwMUmwOVMh|ryP NFXX[pNUSU6JRWK=
C32 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHCTWM2OD1zLkG5NFg5KM7:TR?= MWjTRW5ITVJ?
HCC2157 M{joemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTvXGUyUUN3ME2xMlE6PDl2IN88US=> M1HB[3NCVkeHUh?=
COLO-792 NYnVTGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMkCwO|Eh|ryP NHPsZVJUSU6JRWK=
ES7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;4fY1KSzVyPUGuNlc6PTFizszN MmXLV2FPT0WU
HEL MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLM[YhKSzVyPUGuN|ExOjlizszN MYPTRW5ITVJ?
ES4 NVG4Wo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{S5PVgh|ryP NGXsOmRUSU6JRWK=
NCI-SNU-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf4TWM2OD1zLkO2OVU2KM7:TR?= M13rVXNCVkeHUh?=
MDA-MB-415 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnPTWM2OD1zLkO4PFUh|ryP MYHTRW5ITVJ?
NCI-H2342 NEXlXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn6UWNKSzVyPUGuOFAzPjlizszN MYPTRW5ITVJ?
NB69 NVrKNFVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PMSWlEPTB;MT60OlI4OSEQvF2= MlzQV2FPT0WU
D-247MG MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD1zLkWxNVIzKM7:TR?= M2XRfXNCVkeHUh?=
SCC-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq5W|ZRUUN3ME2xMlU6QDh5IN88US=> MmnJV2FPT0WU
HuH-7 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;yOGlEPTB;MT62O|I6OyEQvF2= NWT5W5lLW0GQR1XS
A388 NET5N|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLTUFF7UUN3ME2xMlY5PzJ2IN88US=> M{jrcXNCVkeHUh?=
Calu-3 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjIRopQUUN3ME2xMlcxPjl5IN88US=> M2DUd3NCVkeHUh?=
NCI-H1648 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYriWXg4UUN3ME2xMlcyPDF6IN88US=> MVPTRW5ITVJ?
NCI-H2052 NI[zXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LOSWlEPTB;MT63NlIxOSEQvF2= NUTjfYZMW0GQR1XS
Ramos-2G6-4C10 M1rMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljpTWM2OD1zLkezOlU3KM7:TR?= Mn3OV2FPT0WU
DEL M3\LW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrLTWM2OD1zLke0OlkzKM7:TR?= NHLZWHZUSU6JRWK=
SNU-423 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTDTWM2OD1zLke4NVU4KM7:TR?= NUf4T4FFW0GQR1XS
COR-L23 M1Hj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2zR|BKSzVyPUGuO|k5PzRizszN NVGwbYs6W0GQR1XS
OMC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vNmlEPTB;MT64OlAyPiEQvF2= NHPGVI9USU6JRWK=
EW-11 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37MemlEPTB;MT65OVY2PyEQvF2= NUj1WWs5W0GQR1XS
HSC-3 NHm3OXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLxNXpQUUN3ME2xMlk3OzZ3IN88US=> MYXTRW5ITVJ?
MLMA Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3TWM2OD1zLkm2Olc4KM7:TR?= NX:yb25sW0GQR1XS
RCM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnPXGR4UUN3ME2yMlAxOzl7IN88US=> M2TzPXNCVkeHUh?=
MFE-280 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\U[VJwUUN3ME2yMlAzQDR6IN88US=> M4jxWXNCVkeHUh?=
ES8 NFLGPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLCSotMUUN3ME2yMlI2PDdzIN88US=> MWTTRW5ITVJ?
TE-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHTUmF{UUN3ME2yMlI6PDd|IN88US=> NXjrcnQ3W0GQR1XS
HuO-3N1 NHLndJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1iyVmlEPTB;Mj60PFc5KM7:TR?= NXWxW3lIW0GQR1XS
MHH-NB-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJwNUGxOVgh|ryP NGTWTGNUSU6JRWK=
TGBC11TKB M3Owfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW0R2dKSzVyPUKuOVc3QDFizszN M1XHfXNCVkeHUh?=
HOP-92 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjPTWM2OD1{LkW4O|Q{KM7:TR?= MY\TRW5ITVJ?
IGR-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGzcJdKSzVyPUKuOlIxOzVizszN Mli3V2FPT0WU
GOTO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwNkWzO|ch|ryP M1PQcXNCVkeHUh?=
NCI-H1650 M3GxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:yTWM2OD1{LkeyNlE2KM7:TR?= MXLTRW5ITVJ?
NCI-H1581 MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKwVWNKSzVyPUKuO|k3QDFizszN NGrieWFUSU6JRWK=
NCI-H2405 NX[5Npl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL6WXJKSzVyPUKuPFI4QDJizszN Mn\JV2FPT0WU
U-118-MG NG[3dmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFiwS|lKSzVyPUKuPVY1QTFizszN Mnj3V2FPT0WU
DoTc2-4510 M{DINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv0TWM2OD1|LkCxOFE4KM7:TR?= MXfTRW5ITVJ?
NCI-H596 M1ewVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfYeYpQUUN3ME2zMlA1QTl5IN88US=> M1;NbnNCVkeHUh?=
MPP-89 M3rwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fnS2lEPTB;Mz6wOVY3PiEQvF2= NWrod5RjW0GQR1XS
GCIY M4nqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX2PXFoUUN3ME2zMlIxPDlzIN88US=> M1\ie3NCVkeHUh?=
SW626 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S3[2lEPTB;Mz6yOFU1OyEQvF2= NH36ZVhUSU6JRWK=
OCI-AML2 NI\qZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTS2NKSzVyPUOuN|EzPzJizszN MV7TRW5ITVJ?
NBsusSR MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD1|LkO0PVM5KM7:TR?= M2fyS3NCVkeHUh?=
AN3-CA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvOTm1KSzVyPUOuOFQzOzhizszN NYjFcmE2W0GQR1XS
EFM-19 NVvEfJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n1SGlEPTB;Mz60PFM{QSEQvF2= MlfGV2FPT0WU
RVH-421 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwNU[4O|ch|ryP MYTTRW5ITVJ?
5637 NES3bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnkd3dKSzVyPUOuOlEyODNizszN NIfve4dUSU6JRWK=
PANC-08-13 NYXDZW5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwNkO0O|Ih|ryP NHqyfYdUSU6JRWK=
H9 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLGSYtRUUN3ME2zMlY4OTR2IN88US=> M1i3dHNCVkeHUh?=
KARPAS-299 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TPVmlEPTB;Mz62O|M3OSEQvF2= M{Lhc3NCVkeHUh?=
TE-5 NVrwV5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\3TWM2OD1|LkewO|A6KM7:TR?= M32z[XNCVkeHUh?=
NOS-1 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\STWM2OD1|Lke5PFM1KM7:TR?= NI\ZXIVUSU6JRWK=
HH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNwOEO4Olgh|ryP MljVV2FPT0WU
769-P NFPwN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3NPGY6UUN3ME2zMlg6PTFizszN MmH0V2FPT0WU
CHP-212 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP6dIxiUUN3ME2zMlkzPTR7IN88US=> NWPTNFhwW0GQR1XS
NCI-H82 NV21PWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPLTWM2OD1|Lkm1PVM3KM7:TR?= MWHTRW5ITVJ?
Mo-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwMESzNVIh|ryP MkLuV2FPT0WU
BB65-RCC MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHHW3RvUUN3ME20MlA1Ozl7IN88US=> MULTRW5ITVJ?
SW1990 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDETWM2OD12LkC1PVA5KM7:TR?= NV7xenM1W0GQR1XS
LK-2 NF\lUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm4OWpKSzVyPUSuNVEzQTNizszN MYXTRW5ITVJ?
ES5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;PN4lTUUN3ME20MlE{QTh3IN88US=> NHvzfnlUSU6JRWK=
JVM-3 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPGZW9KSzVyPUSuNVgzOjJizszN M1:4TnNCVkeHUh?=
RPMI-7951 NGTUTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hsb2lEPTB;ND6yNlQyOyEQvF2= M4fBS3NCVkeHUh?=
Calu-6 NHGzdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTRwMke4PFEh|ryP M3XJc3NCVkeHUh?=
LC-2-ad M17YbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[zR49KSzVyPUSuNlk2PjhizszN M4TOeHNCVkeHUh?=
SW954 NYLaXnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwMkm2OkDPxE1? Mn7pV2FPT0WU
H-EMC-SS NVvTXol5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sc3dKSzVyPUSuN|E5OzFizszN M1zIcXNCVkeHUh?=
ES3 NGXpZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELu[HNKSzVyPUSuN|U1PDFizszN M3TMWHNCVkeHUh?=
no-11 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvpTWM2OD12LkO1OVU1KM7:TR?= M4rLcnNCVkeHUh?=
LAN-6 NWfVUWpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6WWdKSzVyPUSuOFUyQDlizszN MY\TRW5ITVJ?
FTC-133 NW\1XYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;6TJg4UUN3ME20MlU{QTVizszN NWrKUlJEW0GQR1XS
8505C MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xye2lEPTB;ND61OFI{KM7:TR?= M4eyXHNCVkeHUh?=
SW620 NGDYW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrpTWM2OD12LkW3NFU4KM7:TR?= M2LRTXNCVkeHUh?=
BCPAP NHHj[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfx[Gt1UUN3ME20MlY{PDhzIN88US=> M1TZXnNCVkeHUh?=
SK-LU-1 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e1RmlEPTB;ND62OlA5QSEQvF2= MUTTRW5ITVJ?
NCI-H1623 NYjCTY5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwN{CyNlgh|ryP MVfTRW5ITVJ?
C2BBe1 NEHaO5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDCTWM2OD12Lke0NFA5KM7:TR?= MX\TRW5ITVJ?
GP5d MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL4N3ZKSzVyPUSuO|g{QDhizszN M{nGdnNCVkeHUh?=
NB6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL6XJhKSzVyPUSuPFYzODRizszN NHrL[HpUSU6JRWK=
MDA-MB-157 NYfnPGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHJWZBKSzVyPUSuPFg4PiEQvF2= NU\NZXdwW0GQR1XS
UMC-11 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\RTWM2OD12Lki4PVY1KM7:TR?= M2rQWHNCVkeHUh?=
HCC1419 NG[xUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ROIx5UUN3ME20MlkxODZ|IN88US=> NGnMUWRUSU6JRWK=
NCI-H2029 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT3d|BKSzVyPUSuPVQyQDVizszN M{Dsd3NCVkeHUh?=
LXF-289 NYLtdIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxXHlKSzVyPUWuNFM4OTlizszN MU\TRW5ITVJ?
KINGS-1 M4TrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYraXFI2UUN3ME21MlA4PzR2IN88US=> NEOxUopUSU6JRWK=
HD-MY-Z MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlbJZKSzVyPUWuNlM6PjlizszN M1rYRXNCVkeHUh?=
ESS-1 NITLZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfLSY5QUUN3ME21MlI2PTl5IN88US=> MVXTRW5ITVJ?
GI-1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTVwMke5NlYh|ryP NIq1XoJUSU6JRWK=
RPMI-2650 NHLS[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXJTWM2OD13LkO2NVYh|ryP MVPTRW5ITVJ?
IA-LM NXnuUZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3GTWM2OD13LkO5PFcyKM7:TR?= NEPHbY1USU6JRWK=
KP-4 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLtTWM2OD13LkS2N|M1KM7:TR?= NIPWc|VUSU6JRWK=
G-402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLTTWM2OD13LkWxPFY2KM7:TR?= M3vWWHNCVkeHUh?=
OS-RC-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XOUGlEPTB;NT61NlYxPCEQvF2= NV\WUWg1W0GQR1XS
NCI-H1155 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DoNGlEPTB;NT61OFk2PSEQvF2= MYTTRW5ITVJ?
OE19 NGPLcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfDXIdKSzVyPUWuOlg3OjRizszN MkjvV2FPT0WU
U-2-OS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\U[Y9KSzVyPUWuPFkxOTNizszN MkDjV2FPT0WU
SCC-15 M4PaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq1[ot3UUN3ME21Mlk{PjZ{IN88US=> M3O0V3NCVkeHUh?=
NCI-H630 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELSS2pKSzVyPUWuPVk1ODRizszN M1ztenNCVkeHUh?=
PFSK-1 NVjJR4ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTZwMEWyOVkh|ryP M1frfnNCVkeHUh?=
NCI-H1770 NHT4TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzxNJBxUUN3ME22MlIxQDd2IN88US=> NH7LRWZUSU6JRWK=
SK-MEL-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjhWm5KSzVyPU[uOFI6OTVizszN NEnEeWdUSU6JRWK=
LB1047-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH2OG5KSzVyPU[uOFc3OjVizszN NVz0WGNRW0GQR1XS
NCI-H446 NWDVVWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknRTWM2OD14Lk[yPVI2KM7:TR?= NFTDWFdUSU6JRWK=
SW780 M{H2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZwN{CxPFUh|ryP NGHsVZhUSU6JRWK=
NEC8 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwN{[2N{DPxE1? NXuyclRQW0GQR1XS
NOMO-1 NYnDOmtvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K1UWlEPTB;Nj63PFEyOSEQvF2= NEThN5VUSU6JRWK=
COLO-668 M{\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTZwOESzPFch|ryP NXPhOo1qW0GQR1XS
MC116 NHLmNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZwOUO4PVch|ryP NHfnXnBUSU6JRWK=
HCC1937 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X2OmlEPTB;Nj65PVI2OSEQvF2= M1PMXnNCVkeHUh?=
NCI-N87 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfLWItKUUN3ME23MlE6Ojl|IN88US=> NXjtRlFUW0GQR1XS
COLO-320-HSR NFL5VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfTTWM2OD15LkKyO|M5KM7:TR?= MWHTRW5ITVJ?
HCC1806 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M161c2lEPTB;Nz6yOlA1PCEQvF2= M1i4NnNCVkeHUh?=
OVCAR-3 NXLtUpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQVWlEPTB;Nz6zN|A{QCEQvF2= M3;1V3NCVkeHUh?=
NUGC-3 NFvOb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHTb2t2UUN3ME23MlM6Pjl2IN88US=> M4HnV3NCVkeHUh?=
SW1783 M3[4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTdwNEOxO|Uh|ryP MYfTRW5ITVJ?
GCT M2K5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH21VmVKSzVyPUeuOVY6ODZizszN NETxe4FUSU6JRWK=
NCI-H2126 NVPhO5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTdwN{O2NlUh|ryP MkfJV2FPT0WU
MEL-HO NGfqUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTdwN{ewOVQh|ryP M3G2dHNCVkeHUh?=
CAPAN-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X2[mlEPTB;Nz63O|M2PyEQvF2= NIHz[HNUSU6JRWK=
SW756 M4LZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfPTWM2OD15Lke4N|M{KM7:TR?= NIK1fpdUSU6JRWK=
SKG-IIIa MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfvTWM2OD15LkixPFkzKM7:TR?= Mn;kV2FPT0WU
HCE-T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYZmZPUUN3ME23Mlg4Pzh|IN88US=> MYXTRW5ITVJ?
Ca-Ski M2DqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\BTmt[UUN3ME23Mlk6Ozh|IN88US=> NYnXcFNoW0GQR1XS
COLO-684 NYrkXIx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILtSldKSzVyPUiuNFE5OThizszN MmLBV2FPT0WU
KYSE-70 M1nvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDrS3hEUUN3ME24MlA4PzJ7IN88US=> MnvTV2FPT0WU
TI-73 NWH4fnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZbHJDUUN3ME24MlI2QDVzIN88US=> NFzzVG1USU6JRWK=
BT-20 NIDXfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TEcWlEPTB;OD6yOlA2OiEQvF2= M4XydXNCVkeHUh?=
MHH-ES-1 M4jKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HIWmlEPTB;OD61NVg{PCEQvF2= NHy2UZVUSU6JRWK=
TE-12 M4DFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3JTWM2OD16LkW5PVMyKM7:TR?= NVLmd3NYW0GQR1XS
YH-13 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW5TGVjUUN3ME24MlYyODB6IN88US=> NVO3cGp6W0GQR1XS
SF126 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i1VGlEPTB;OD64N|g3PSEQvF2= M2rSZnNCVkeHUh?=
J82 NXrqdIh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3cWlEPTB;OD65NFA{QCEQvF2= NILhUZJUSU6JRWK=
RCC10RGB MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn0cXFKSzVyPUiuPVk2PjFizszN MWfTRW5ITVJ?
SK-UT-1 NGTJdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjxSpFKSzVyPUmuNFQ6PDVizszN M4iyT3NCVkeHUh?=
LB2241-RCC MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;aSmlEPTB;OT6xPVE{PyEQvF2= NFTmXG1USU6JRWK=
LB996-RCC M37LcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTlwMUm4PUDPxE1? NV7sVJpyW0GQR1XS
EPLC-272H M{S2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X3OmlEPTB;OT6zO|Y2PyEQvF2= M1jYVHNCVkeHUh?=
CTV-1 NX62T|JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr1Sll[UUN3ME25MlU3PTN{IN88US=> M4i4enNCVkeHUh?=
HSC-2 NYi3em1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS4SmttUUN3ME25MlU4PTVizszN M3T2UnNCVkeHUh?=
SK-MEL-28 NV\3cpFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwNkG4PVMh|ryP MWPTRW5ITVJ?
MMAC-SF NV\VdnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnBV4JtUUN3ME25MlY5PzVizszN MUfTRW5ITVJ?
CP50-MEL-B NWjvXlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nzTmlEPTB;OT63OVc5OiEQvF2= MUPTRW5ITVJ?
HT-1080 NXi4cVB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITYeFBKSzVyPUmuO|c4OzlizszN NITRU41USU6JRWK=
HEC-1 M2PoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFyLkOzOVIh|ryP M3i1XXNCVkeHUh?=
AGS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFyLkO3OEDPxE1? MV7TRW5ITVJ?
GAMG NVTrVVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[wcGlEPTB;MUCuOVE3OiEQvF2= MnzuV2FPT0WU
SW48 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnQT|NwUUN3ME2xNE42OTh7IN88US=> NGDFTlZUSU6JRWK=
U031 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61TWM2OD1zMD61PVA5KM7:TR?= M4fsdXNCVkeHUh?=
OVCAR-5 NIHDTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFyLk[0Nlkh|ryP NF\qZWhUSU6JRWK=
SF295 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPzNlVwUUN3ME2xNE43PzB2IN88US=> M3PDWHNCVkeHUh?=
BHT-101 NHPqWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\DU2lEPTB;MUCuO|E4PyEQvF2= MnTQV2FPT0WU
VMRC-RCZ M1ewfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmPWlEPTB;MUGuN|IxOSEQvF2= MmrRV2FPT0WU
ACHN NIPwVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK1NVJoUUN3ME2xNU41OjFzIN88US=> NVLWU4ZUW0GQR1XS
NCI-H526 M{jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHScohuUUN3ME2xNU42ODR|IN88US=> MVLTRW5ITVJ?
MN-60 NIHpbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXKR41KSzVyPUGxMlU{QSEQvF2= NXn2TWVkW0GQR1XS
NCI-H2291 NX76SpZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTkbllqUUN3ME2xNU42PDZ4IN88US=> M1P6ZXNCVkeHUh?=
SCC-25 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvnUJd3UUN3ME2xNU44PTV4IN88US=> NHS0UmJUSU6JRWK=
SK-MEL-2 NV\yTpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z3N2lEPTB;MUGuO|Y{PyEQvF2= NHfDPZRUSU6JRWK=
SN12C NHjOOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXhTWM2OD1zMT65N|U2KM7:TR?= NX[xV3VzW0GQR1XS
NCI-H69 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WzOGlEPTB;MUKuOFI{PCEQvF2= NWPOOnFHW0GQR1XS
ME-180 NFjyR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD1zMj63NFU1KM7:TR?= NXPnW4l[W0GQR1XS
MC-IXC M4nIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\xT2lEPTB;MUKuO|UyQCEQvF2= MYfTRW5ITVJ?
NCI-H2347 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfqTWM2OD1zMj63OlE1KM7:TR?= NU\xfZB5W0GQR1XS
M059J MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnPPHJEUUN3ME2xNk44PzJ5IN88US=> NYTJeHpsW0GQR1XS
A2058 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrZPWtKSzVyPUGyMlg3QDFizszN M{D5bXNCVkeHUh?=
VA-ES-BJ NIPnPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOwOHZKSzVyPUGyMlg4QDVizszN MYrTRW5ITVJ?
Ca9-22 NWS0eolXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTu[IVKSzVyPUGyMlk1PTFizszN MX7TRW5ITVJ?
KNS-42 M2nSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrmW2pHUUN3ME2xNk46QTh2IN88US=> M4LWNnNCVkeHUh?=
LoVo Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf4boRKSzVyPUGzMlI{OTNizszN NE\ES2lUSU6JRWK=
AM-38 NV7yO3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqwTWM2OD1zMz6yOVY3KM7:TR?= MWfTRW5ITVJ?
NB5 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTF|LkO3OVIh|ryP NHX1OnlUSU6JRWK=
L-363 NI\3d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PBSmlEPTB;MUOuOFA{OyEQvF2= Mmn2V2FPT0WU
SK-MEL-30 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rJNWlEPTB;MUSuNFY1PSEQvF2= M4HxZXNCVkeHUh?=
NCI-H1563 NGHRdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0eGlEPTB;MUSuOlA{QSEQvF2= Mnn6V2FPT0WU
NCI-H2228 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF2Lk[wO|ch|ryP NEfCfnpUSU6JRWK=
MFM-223 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPtTWM2OD1zNT6xPFE{KM7:TR?= NWrOXFNYW0GQR1XS
LB831-BLC NGfDVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7sfmVKSzVyPUG1MlI4PjdizszN MnT2V2FPT0WU
SW872 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF3LkOwPFYh|ryP NUnFN3piW0GQR1XS
NCI-H522 MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO3TWM2OD1zNT6zN|A3KM7:TR?= MofBV2FPT0WU
EW-1 M1ftOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPj[GxKSzVyPUG1MlU1PjJizszN M2TE[3NCVkeHUh?=
HN NIewd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\tdGlEPTB;MUWuOVk1OiEQvF2= NGXIU45USU6JRWK=
SW837 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7aPHdqUUN3ME2xOU44QDR5IN88US=> NWPBfJhlW0GQR1XS
SCC-9 NFPmdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXxOoxkUUN3ME2xOU45OTF2IN88US=> M3P6XHNCVkeHUh?=
MKN7 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGntbFNKSzVyPUG1Mlk4OzJizszN NIr0TYZUSU6JRWK=
KYSE-410 NXjwPI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f3bWlEPTB;MU[uOVkyKM7:TR?= MmXPV2FPT0WU
SK-N-DZ M1PwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF4Lk[xNVYh|ryP MWPTRW5ITVJ?
COR-L105 NIfze21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF4Lk[1Nlgh|ryP NIr5XpVUSU6JRWK=
LB2518-MEL NGOzdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF4LkizPFkh|ryP NF60NHFUSU6JRWK=
OVCAR-4 NVr4RZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DCeGlEPTB;MU[uPFg3OiEQvF2= NIfVPFFUSU6JRWK=
TK10 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPTe2ZKSzVyPUG2Mlk1PzNizszN M1rSfXNCVkeHUh?=
KNS-62 NU[wV2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj1THYyUUN3ME2xOk46Pzd5IN88US=> M1LmPHNCVkeHUh?=
RPMI-8866 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzOmZKSzVyPUG3MlE4OzJizszN NUj1eFdoW0GQR1XS
HuP-T4 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW4SpZKSzVyPUG3MlI1QTVizszN MliyV2FPT0WU
CGTH-W-1 M3XBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[xTWM2OD1zNz61NlE6KM7:TR?= M1juZ3NCVkeHUh?=
T-24 M3\CUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLiTWM2OD1zNz61N|Q4KM7:TR?= M4T2PXNCVkeHUh?=
HT-3 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rWU2lEPTB;MUeuOVkyPCEQvF2= M4\IU3NCVkeHUh?=
KS-1 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfq[4ZKSzVyPUG3MlY4OyEQvF2= MlGyV2FPT0WU
NCI-H1792 M1L1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF5Lke5PEDPxE1? MW\TRW5ITVJ?
ABC-1 NFyyZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX6TWM2OD1zNz64NVQyKM7:TR?= NFW3WmRUSU6JRWK=
BPH-1 NFK1VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ncWlEPTB;MUiuNVY5PSEQvF2= M1SwdHNCVkeHUh?=
A431 NH7G[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3BTWM2OD1zOD60NVI4KM7:TR?= MV3TRW5ITVJ?
T98G M1ixb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzaV4JKSzVyPUG4MlUyPTdizszN MWXTRW5ITVJ?
BHY M{m1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF6Lki2PUDPxE1? M3XYeHNCVkeHUh?=
Capan-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLJSWpKSzVyPUG4MlkxPzhizszN NF;kW4tUSU6JRWK=
MDA-MB-175-VII NIHmNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3OcY4xUUN3ME2xPE46OjB7IN88US=> MnvvV2FPT0WU
CAL-27 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF7LkC0PFch|ryP MnvwV2FPT0WU
AsPC-1 NUizeY56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P2TWlEPTB;MUmuPFY2PyEQvF2= MULTRW5ITVJ?
KU812 NEf4V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2cHdbUUN3ME2xPU46PTd|IN88US=> NVrBOoJzW0GQR1XS
NCI-H441 NYX6e|d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTlV5VKSzVyPUKwMlAxOSEQvF2= NUG0U2RbW0GQR1XS
Mewo NVnPTJBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJyLkGyPFgh|ryP M1HsV3NCVkeHUh?=
SK-MEL-24 NYDpNXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS1SmJKSzVyPUKwMlE1PzdizszN NGOzNnFUSU6JRWK=
NCI-H727 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH2TVBKSzVyPUKwMlI4ODRizszN MnnrV2FPT0WU
EKVX MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJyLk[wOkDPxE1? NVPyTJM6W0GQR1XS
RT-112 Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nvRmlEPTB;MkCuOlEzOiEQvF2= Ml7XV2FPT0WU
CAMA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjyTWM2OD1{MD65PFA{KM7:TR?= NVL2OG9HW0GQR1XS
SW900 M2e5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnL[ZNKSzVyPUKxMlAyPDlizszN MV\TRW5ITVJ?
NCI-H23 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m1dGlEPTB;MkGuNVI4PyEQvF2= NXrjTHJsW0GQR1XS
SK-PN-DW MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTrSFdKSzVyPUKxMlE3PDlizszN NYXpOZZjW0GQR1XS
BB30-HNC NFzFOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnEOWNKSzVyPUKxMlI4PDVizszN M{PTUXNCVkeHUh?=
VM-CUB-1 NXX1WFk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;Z[255UUN3ME2yNU4{PTN4IN88US=> NE\rXXFUSU6JRWK=
IST-MEL1 M2W5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLBTWM2OD1{MT6zOlkzKM7:TR?= NISzeGpUSU6JRWK=
CTB-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHWTWM2OD1{MT60O|U2KM7:TR?= MYDTRW5ITVJ?
LCLC-103H MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ{LkG1PFIh|ryP MVzTRW5ITVJ?
PANC-03-27 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rpcmlEPTB;MkKuOVE3QSEQvF2= MoK2V2FPT0WU
HTC-C3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnGb|RKSzVyPUKyMlU2PTVizszN NFTjWGdUSU6JRWK=
TE-8 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ|LkK1OlUh|ryP NYPoeGNIW0GQR1XS
NCI-H292 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tj[2lEPTB;MkWuN|U{PiEQvF2= NE[3bGRUSU6JRWK=
COLO-680N NG\SbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD1{NT62N|I6KM7:TR?= MYrTRW5ITVJ?
KYSE-520 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7BNGtKSzVyPUK1MlY1PCEQvF2= MXTTRW5ITVJ?
NB10 NWPteIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP4TWM2OD1{Nj6zNVE4KM7:TR?= NF3mbnVUSU6JRWK=
NCI-H661 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzJTWM2OD1{Nj60O|E{KM7:TR?= MVPTRW5ITVJ?
GMS-10 M2nCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;rVWlEPTB;Mk[uPFY{QCEQvF2= NF;HZmlUSU6JRWK=
NCI-H2122 NU\oeXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1{Nj65PVk5KM7:TR?= M{L0SnNCVkeHUh?=
OVCAR-8 M2XmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXQTWM2OD1{Nz6wOlM5KM7:TR?= MV;TRW5ITVJ?
DJM-1 NGnBZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPLTWM2OD1{Nz6xOFU1KM7:TR?= NE\PWZdUSU6JRWK=
UACC-893 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PyW2lEPTB;MkeuPVg4QCEQvF2= MmO3V2FPT0WU
C8166 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO4TWM2OD1{OD62PVM5KM7:TR?= NVTuPY84W0GQR1XS
NCI-H1693 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hOpdNUUN3ME2yPE43QTd3IN88US=> NULOWoRwW0GQR1XS
TYK-nu MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHDd|VKSzVyPUOwMlA{PDVizszN MV;TRW5ITVJ?
SW1710 NFvjWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;zVWlEPTB;M{CuNVI3KM7:TR?= MYjTRW5ITVJ?
A375 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILRZnJKSzVyPUOwMlMzPDNizszN MXPTRW5ITVJ?
HMV-II MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTZTWM2OD1|MT6zOVkzKM7:TR?= MVLTRW5ITVJ?
NCI-H2087 NYTPeJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hte2lEPTB;M{GuOlM2OiEQvF2= NFOyXpJUSU6JRWK=
CAL-54 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj5TWM2OD1|MT63NlQyKM7:TR?= NF7i[YRUSU6JRWK=
HCC70 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN{LkGzPFch|ryP NFfpN3lUSU6JRWK=
ES1 NVzyN5VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1SXVCUUN3ME2zNk4{ODZ{IN88US=> MWrTRW5ITVJ?
NCI-H1355 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXWTWM2OD1|Mz6yNFQh|ryP M{PobXNCVkeHUh?=
CFPAC-1 M3ixfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\uTWM2OD1|Mz6yN|MzKM7:TR?= MlfIV2FPT0WU
MKN28 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWyWJFKSzVyPUOzMlM5ODlizszN M3r0WnNCVkeHUh?=
HDLM-2 NHzJWZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPHeVhKSzVyPUOzMlY6OzFizszN MYHTRW5ITVJ?
PANC-10-05 M2HRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrUZ|k6UUN3ME2zOE4yODF2IN88US=> Ml25V2FPT0WU
SAS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj3Xo5KSzVyPUO0MlQ2PjVizszN NUD4O2w4W0GQR1XS
HCC1395 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf3TWM2OD1|ND63NVg3KM7:TR?= Ml\lV2FPT0WU
8305C M1PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrYTWM2OD1|NT64OFE2KM7:TR?= NFvrOmZUSU6JRWK=
KM12 NXLoOFhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jkbmlEPTB;M{[uO|U1PyEQvF2= MlfEV2FPT0WU
SW1116 NUTGRppRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXUTWM2OD1|Nz61PVkzKM7:TR?= NFe3T2NUSU6JRWK=
SK-MEL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTSTWM2OD1|OD6zN|g6KM7:TR?= MYfTRW5ITVJ?
HCC2218 M2X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHyeYJ2UUN3ME2zPE43PTF7IN88US=> Mm\xV2FPT0WU
T84 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j4RWlEPTB;M{iuO|QxQSEQvF2= MXLTRW5ITVJ?
ETK-1 NV;mbos2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M121XmlEPTB;M{muNFIzKM7:TR?= MVvTRW5ITVJ?
COLO-800 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELOZ3VKSzVyPUO5MlM5PjhizszN NUjabHMyW0GQR1XS
CAL-12T M3W5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTxTWM2OD1|OT61NlgyKM7:TR?= MV7TRW5ITVJ?
ACN MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISydVBKSzVyPUSwMlQ6OTFizszN MmfaV2FPT0WU
SJSA-1 NETPemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXmOHlKSzVyPUSxMlE2QTZizszN MnfWV2FPT0WU
PSN1 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonYTWM2OD12MT6xO|Q6KM7:TR?= MWnTRW5ITVJ?
D-566MG NVfIeGNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrtPGxwUUN3ME20NU4zODh4IN88US=> MkXqV2FPT0WU
EGI-1 NG[2SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR{LkSyPEDPxE1? NXrPUItoW0GQR1XS
A204 NXH4TZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTR{Lk[zPFgh|ryP M2HzSXNCVkeHUh?=
Saos-2 M4D2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR{LkizOlkh|ryP NYDZfJY{W0GQR1XS
SNU-C2B MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxe2xIUUN3ME20N{43QDd6IN88US=> NXXyTVFjW0GQR1XS
HLE NV\PSWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq2V3NKSzVyPUS0MlA5PTZizszN MonhV2FPT0WU
SW1463 NFTQV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPR[VlKSzVyPUS0Mlk6PzFizszN MXTTRW5ITVJ?
DSH1 NV;ONVR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR3LkCwN|Mh|ryP NV3tV5Z2W0GQR1XS
MCF7 M13R[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXCTWM2OD12NT61NFUyKM7:TR?= NIfIUZBUSU6JRWK=
K5 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ndmlEPTB;NEWuPVQxPSEQvF2= NYPLdpZHW0GQR1XS
NCI-H358 M4XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HPeGlEPTB;NEeuNlE2KM7:TR?= MWjTRW5ITVJ?
NCI-H2030 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTR5LkKzO|Qh|ryP NHSzdVdUSU6JRWK=
SW948 NULVWIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K3SWlEPTB;NEeuOFY1KM7:TR?= M3;lSHNCVkeHUh?=
BALL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR5Lk[xOlgh|ryP NUfWeplVW0GQR1XS
TE-9 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPjU2VKSzVyPUS3Mlk2QDFizszN MlXqV2FPT0WU
SK-N-FI Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTR6LkCzOVgh|ryP MYnTRW5ITVJ?
KALS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP0TWM2OD12OD6xNlg6KM7:TR?= NIryeWVUSU6JRWK=
HO-1-N-1 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTR6Lke0OFUh|ryP NGrwS5FUSU6JRWK=
NCI-H2452 NWjFUm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTR7LkGxOVIh|ryP NVXmb2FvW0GQR1XS
OC-314 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe1WlFKSzVyPUS5MlY5OzRizszN NFzQWGZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID